Hikal Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vl1x6pd3ymhcqfenij0if0vp.pdf

Key Takeaways


Crop Protection: The Recovery Bet

Vimal Kulshrestha: "Yes, so we expect it to be towards Q3 or Q4 of current financial year. You know, it is difficult to specifically tell you the period, but this should be around Q3 or Q4 of current financial year."

Pharma: Short-Term Pain for Capacity Gains


Animal Health: Early Innings, Long Gestation


Margins & Profitability: The Lag Effect

Anish Swadi: "the focus, as he mentioned, is on profitability, right? How do we improve the margin profile and the net profit? That's the key focus of the business across all the verticals."

The Pipeline: Inquiry-Rich, Revenue-Distant


Guidance & Commitments

CommitmentSpecificsTimeline
Crop Protection demand recoveryIndustry stabilization and destocking improvement expectedQ3 or Q4 FY25
Pharma CDMO normalizationDe-stocking impact to ease; pushed-back deliveries to improveSecond half FY25
Revenue growth10–15% CAGR across all businessesFY26 onwards (3-year horizon)
EBITDA marginReturn to 18–20%Post FY26, over the next few years
API product launches2–3 new products per year from an 8–9 product pipelineOngoing
Two CDMO products at peak potentialPeak revenue contribution from two in-production CDMO productsWithin 2 years
NCE Phase-3 intermediates ramp-upTwo advanced intermediates begin commercial ramp2026–27
Animal Health validationsSeveral more product validations completed, then submitted for registrationBy year-end FY25
Animal Health commercializationValidated products become commercial after 14–16 month lag; ₹300–₹400 crore business ambition3–4 year horizon
New molecule peak potentialFull peak revenue from new molecules in pipeline4–5 years from now
Debt reductionDebt to start coming down meaningfullyFY26 onwards

Key Metrics

MetricQ1 FY25
Revenue₹406 cr, combined Crop Protection ₹177 cr and Pharma ₹229 cr
EBITDA₹58 cr, 14.3% margin vs ₹50 cr (12.9%) YoY, growth of 16%
EBITDA margin14.3%, up 140 bps YoY from 12.9%
Profit before tax impact₹10 cr combined impact from higher depreciation and interest on new asset capitalization
Crop Protection revenue₹177 cr
Crop Protection EBIT margin11.6%, up 110 bps YoY
Pharmaceutical revenue₹229 cr
Pharmaceutical EBIT margindecreased 60 bps YoY
R&D spend~4% of total sales
Gross margin (blended)close to 45%
CAPEX guidance (FY25)₹120–₹140 cr, mostly debottlenecking and maintenance
Total debt₹759 cr, down ₹45 cr QoQ from ₹804 cr
Crop Protection capacity utilization~60%
Pharma capacity utilization~65%, expected to increase from Q2 onwards
Animal Health long-term revenue potential₹300–₹400 cr over 3–4 year horizon